Neuronal synapse illustration showing neurotransmitter release, symbolizing how BK channel openers restore balance in Fragile X syndrome.

BK Channel Openers: From FRAXA Seed Funding to Big Pharma Investment and Trials

See how FRAXA’s early grants propelled Fragile X research from lab discoveries to industry momentum, with partners advancing therapies into trials.

Read More »

BK Channel Openers: A New Hope for Fragile X Treatment – Insights from Kaerus Bioscience CEO Robert Ring

Kaerus Bioscience’s BK channel openers for Fragile X syndrome are advancing through Phase 1 trials, offering hope for new treatments with FRAXA’s continued support.

Read More »
FRAXA Research Team. From left to right: Sandrine Lefeuvre (PhD, Pharmacologist), Sylvain Briault (MD, PhD, head of the team), Julie Maublanc (PhD student, Pharmacologist), Olivier Perche (PhD, hospital engineer), Béatrice Laudier (MD, PhD student), Betty Hébert (PhD student), Arnaud Menuet (PhD, assistant professor) and Jacques Pichon (Professor, Dr es Science).

Sensory Hypersensibility in Fragile X Syndrome and BK Channel Openers

With $366,100 in grants from FRAXA Research Foundation, these investigators at the University of Orleans studied sensory abnormalities in Fragile X mice and test the ability of a class of drugs, BK channel openers, to rescue these abnormalities.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (46)